Breakfree-SSc: A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis (clinicaltrials.gov) - Sep 19, 2026 - P3 | N=92 | Not yet recruiting | Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | Initiation date: Aug 2026 ➔ Feb 2027
Trial initiation date • Immunology • Scleroderma • Systemic Sclerosis
|